Last reviewed · How we verify
NCT06104943: STRIREG
Stockholm hyperTRIglyceridemia REGister (STRIREG) Study
trial testing Heredity for cardiovascular disease in Familial Hypertriglyceridemia in 3,607,819 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2021
Quick facts
| Lead sponsor | Region Stockholm |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 3,607,819 |
| Start date | 1 January 2000 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- Heredity for cardiovascular disease
- Heredity for pancreatitis
- Heredity for type 2 diabetes
- Heredity for hypertriglyceridemia
Conditions studied
- Familial Hypertriglyceridemia — all drugs for Familial Hypertriglyceridemia →
Sponsor
Region Stockholm — full company profile →
Who can join
Eligibility, any sex, with Familial Hypertriglyceridemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The STRIREG study is a retrospective longitudinal general population-based register study including all individuals who had had at least one plasma Tg measurement between 1st January 2000 and 31st December 2021 at Karolinska University Laboratory or Unilabs AB in Region Stockholm (population 2.41 million 2021). The exclusion criteria were a lack of a unique Swedish personal identification number (PIN). The index population consisted of 1,460,184 individuals between the age 0 and 107 years. The index population was extended to form the complete cohort (n=3,607,819) by associating the parents and the siblings (n=2,147,635) to the indexes by interlinkage of personal identification numbers via the Multi-Generation register (see below). The study baseline for the index population was defined as the date for participant's first Tg measurement.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Relation among hypertriglyceridaemia, cardiometabolic disease, and hereditary factors-design and rationale of the Stockholm hyperTRIglyceridaemia REGister study.
Andersson DP, Littmann K, Kindborg G, Eklund D, et al · · 2024 · cited 2× · PMID 38487365 · DOI 10.1093/ehjopen/oeae010
Verify or expand the search:
- PubMed search for NCT06104943
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Region Stockholm trials
Trials by the same sponsor.
- NCT06304363 — Braining - Evaluation of Acute Effects of Physical Exercise · NA · not yet recruiting
- NCT07089771 — Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy · NA · not yet recruiting
- NCT07503951 — Cognitive Behavior Therapy in Psychiatric Inpatient Care · NA · not yet recruiting
- NCT07434219 — A Group Based Psychoeducational Intervention for Partners of Child Sexual Abuse Material Offenders. · NA · not yet recruiting
- NCT07464730 — Postoperative High-flow Nasal Oxygenation After High-risk Surgery in the Frail Adult · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06104943 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region Stockholm
- Last refreshed: 27 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06104943.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing